- Home
- CLEU vs PTN Comparison
CLEU vs PTN Comparison
Compare CLEU & PTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLEU
- PTN
- Stock Information
- Founded
- CLEU 2011
- PTN 1986
- Country
- CLEU China
- PTN United States
- Employees
- CLEU N/A
- PTN N/A
- Industry
- CLEU Other Consumer Services
- PTN Biotechnology: Pharmaceutical Preparations
- Sector
- CLEU Real Estate
- PTN Health Care
- Exchange
- CLEU Nasdaq
- PTN Nasdaq
- Market Cap
- CLEU 20.0M
- PTN 20.9M
- IPO Year
- CLEU 2020
- PTN 1993
- Fundamental
- Price
- CLEU $1.93
- PTN $0.54
- Analyst Decision
- CLEU
- PTN Strong Buy
- Analyst Count
- CLEU 0
- PTN 1
- Target Price
- CLEU N/A
- PTN $7.00
- AVG Volume (30 Days)
- CLEU 174.8K
- PTN 904.9K
- Earning Date
- CLEU 10-11-2024
- PTN 05-14-2025
- Dividend Yield
- CLEU N/A
- PTN N/A
- EPS Growth
- CLEU N/A
- PTN N/A
- EPS
- CLEU N/A
- PTN N/A
- Revenue
- CLEU $2,413,409.00
- PTN $350,000.00
- Revenue This Year
- CLEU N/A
- PTN N/A
- Revenue Next Year
- CLEU N/A
- PTN N/A
- P/E Ratio
- CLEU N/A
- PTN N/A
- Revenue Growth
- CLEU N/A
- PTN N/A
- 52 Week Low
- CLEU $0.05
- PTN $0.46
- 52 Week High
- CLEU $7.90
- PTN $2.88
- Technical
- Relative Strength Index (RSI)
- CLEU 50.10
- PTN 28.90
- Support Level
- CLEU $1.80
- PTN $0.68
- Resistance Level
- CLEU $2.24
- PTN $0.84
- Average True Range (ATR)
- CLEU 0.30
- PTN 0.08
- MACD
- CLEU -0.02
- PTN -0.02
- Stochastic Oscillator
- CLEU 14.61
- PTN 20.22
About CLEU China Liberal Education Holdings Limited
China Liberal Education Holdings Ltd is an educational service provider operating in China. The company's operating segment includes Sino-foreign Jointly Managed Academic Programs, textbooks and course material sales, Overseas Study Consulting Services, Technological Consulting Services for Smart Campus Solutions and Tailored Job Readiness Training Services. Geographically, it derives revenue from China.
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.